CTS: 3 Key Takeaways for Long-Term Investors
Gross margins hit record highs, but management warns they'll normalize as project timing balances out.
1. CTS increased its full-year sales guidance to between $580 million and $590 million, driven by a move toward higher-margin medical and industrial markets as light vehicle production slows. This strategic shift was highlighted in the company's Q3 2026 earnings call on Oct. 27, 2026.
2. The acquisition of Millar for $50 million in cash bolstered CTS's medical sensor revenue by $30 million, augmenting their strategic push into healthcare applications. Millar's integration has contributed to a 21% year-over-year growth in medical segment sales, reaching $27 million.
3. Gross margin expanded to a record 42.2%, driven by favorable project timing, operational execution, and a favorable impact from foreign currency changes. This improvement was particularly strong in the defense segment, which generated a 1.91 book-to-bill ratio, indicating robust demand. CTS anticipates normalizing gross margins in future quarters as project schedules balance out.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
Also reported by 1 other outlet
- CTS: 3 Key Takeaways for Long-Term Investors nasdaq.com
